Dissertation > Excellent graduate degree dissertation topics show

Furazolidone-based Triple Therapy for Helicobacter Pylori: A Clinical Analysis of 108 Cases

Author: ZengLiFang
Tutor: ChenAnHai
School: Zunyi Medical College,
Course: Department of Gastroenterology,
Keywords: triple therapy Helicobacter pylori Furazolidone Pantoprazole cost-effectiveness analysis
CLC: R57
Type: Master's thesis
Year: 2011
Downloads: 30
Quote: 0
Read: Download Dissertation

Abstract


Objective:To observe the efficacy, safety and symptom improvement of Furazolidone-based therapy in the eradication of Helicobacter pylori infection, calculate the cost of treatment, analyze the cost-effectiveness(C/E) and aim at looking for cost-effective of treatment regimens for the eradication of Helicobacter pylori.Methods:Patients were divided randomly into three groups:one group received Furazolidone-based bigeminy therapy (Group A), the second group received Furazolidone-based triple therapy (Group B), and the third group received standard triple therapy(Group C),36 patients in each group. Group A was administered pantoprazole capsules 40mg bid plus furazolidone tablets 100mg tid, for 1 week; Group B was administered pantoprazole capsules 40mg bid plus furazolidone tablets 100mg tid plus colloidal bismuth pectin dry suspension 150mg qid, for 1 week; Group C was administered pantoprazole capsules 40mg bid plus amoxicillin dicloxacillin sodium capsules 1.5g bid plus Clarithromycin sustained-release capsules 0.5g qd, for 1 week.①Record the detailed case history of every patient; the results of their endoscopy, their treatment and countercheck; and the side effects of medications. Hp diagnosis criteria:rapid urease test positive and W-S silver staining positive. Undertake rapid urease test and W-S silver staining later. The follow-up was performed at the first week, the second week, the third week and the fifth week after the treatment.②Observe Hp eradication one month after completion of therapy.③Analyze cost-effectiveness among the above three kinds of treatments with Pharmacoeconomics.Results:2 patients missed out on follow-up in Group A,1 patient in Group B and Group C respectively.①The eradication rate of Group A, Group B and Group C were 64.7%, 91.4% and 88.6%, respectively; the difference in the eradication rate of Helicobacter pylori between Group A and Group C was significant(P<0.05), while the difference between Group B and Group C was not significant (P> 0.05).②In the first week, the incidence of side effects among Group A, Group B and Group C were 14.7%,11.4% and 8.6%, respectively; no significant difference was found (P> 0.05) between the furazolidone-based group and the standard triple group; in the second week and the fifth week, there were no further side- effects.③In the second week and the third week, there was significant difference(P<0.05)in the improvement of symptoms between Group A and Group C, while there was not significant difference(P> 0.05) between Group B and Group C in the fifth week, no significant difference was observed (P> 0.05) between the furazolidone-based group and the standard triple group.④Pharmacoeconomic analysis showed that the ratio of cost-effectiveness of the furazolidone-based triple group was obviously better than that of the standard triple group.Conclusion:The efficacy and the incidence of side-effects of the furazolidone, pantoprazole and colloidal bismuth pectin dry suspension triple therapy is similar to that of the standard triple therapy. Based on cost-effectiveness analysis, the furazolidone-based triple therapy was superior to the standard triple therapy.

Related Dissertations

  1. Epidemiology of Helicobacter Pylori Infection and Associated Factors among Workers in Dalian Port Group,R181.3
  2. Antibiotic-resistance of Helicobacter Pylori and Effects of Helicobacter Pylori Eradication on Different Subtypes of Functional Dyspepsia,R57
  3. Kunming Children Helicobacter pylori infection and risk factors,R725.7
  4. Follow-up Studies of 140 Gastric Mucosal Epithelial Dysplasia Patients,R735.2
  5. Cost-effectiveness Analysis on Addition of a New Sedative and Analgesic Drug Dexmedetomidine Hydrochloride to General Anesthesia Program,R614
  6. Cost-effectiveness Analysis of Therapeutic Regimes for the Eradication of Helicobacter Pylori in XinJiang Region,R573.1
  7. The Relationship among Gastric Cancer and H.pylori Infection, the Expression of Matrix Metalloproteinase-1 and Matrix Metalloproteinase-10,R735.2
  8. Both methods treat Sanders Ⅱ type with fractures and cost - effectiveness analysis,R687.3
  9. Different combinations of antihypertensive drugs in the treatment of essential hypertension Economic Evaluation,R544.1
  10. The Comparison of Four Methods in Diagnosis and 10-day Sequential Therapy in Clinical Research of Helicobacter Pylori Infection in Children,R725.7
  11. Clinical Research on the Treatment of the Acute Pelvic Inflammatory Disease (Syndrome of Damp-heat Stasis) by Huahong Capsule with Antibiotics,R711.33
  12. Analysis on Efficacy and Cost-effectiveness of Four Treatment Methods for Acute Exacerbation of COPD Bacterial Infections,R563.9
  13. The Cost-effectiveness of Standardized Community Diabetes Management,R473.2
  14. Willingness to Pay and Willingness to Accept Evaluation of Effectiveness and Equity of Health Programs,F224.5
  15. Research on China's banking regulatory efficiency,F224
  16. Drug treatment of lower respiratory tract infection Pharmacoeconomic evaluation of,R956
  17. Analysis the Relationship between Helicobaeter Pylori Inefction and Idiopathic Thrombocytopenic Purpura in Children,R725.5
  18. Study of Gastric Epithelial Cells Infected by Helicobacter Pylori on Expression of RECK and Its Modulating Mechanism,R735.2
  19. Helicobacter pylori infection on common complication of cirrhosis risk of,R575.2
  20. Helicobacter pylori infection and TCM syndromes and Tongue,R259
  21. The Effect of Helicobacter Pylori Eradication on Chronic Non-atrophic Gastritis: a Prospective Multi-center Control Study in China,R573.3

CLC: > Medicine, health > Internal Medicine > Digestive and abdominal diseases
© 2012 www.DissertationTopic.Net  Mobile